Viking Therapeutics Stock News

Viking Therapeutics Inc (VKTX) shares closed today at 0.5% above its 52 week low of $4.18, giving the company a market cap of $328M. The stock is currently down 8.7% year-to-date, down 33.6% over the past 12 months, and up 233.3% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 26.4% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 64.5% The company's stock price performance over the past 12 months lags the peer average by 67.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

For years, one of the most dependable sectors, especially for investors who are more conservative, was health care.

SAN DIEGO, Jan. 3, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and

Viking Therapeutics, Inc. (NASDAQ:VKTX)s share price passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $5.61 and traded as low as $4.86. Viking Therapeutics shares last traded at $5.18, with a volume of 841,181 shares. A number of equities analysts have commented on [] The post Viking Therapeutics (NASDAQ:VKTX) Shares Cross Below 50-Day Moving Average of $5.61 appeared first on ETF Daily News .

Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) have been given a consensus rating of Buy by the nine ratings firms that are presently covering the firm, MarketBeat.com reports. Nine investment analysts have rated the stock with a buy recommendation. The average 12 month price objective among analysts that have issued a report on the stock in []

Viking Therapeutics Inc. (NASDAQ:VKTX) shares, rose in value on Friday, 12/17/21, with the stock price up by 5.59% to the previous days close as strong demand from buyers drove the stock to $4.91. Actively observing the price movement in the last trading, the stock closed the session at $4.65, falling within a range of $4.60 Viking Therapeutics Inc. (NASDAQ: VKTX): Whats Next In 2021? Read More »

uniQure (QURE) reports initial data on the first four patients enrolled in the lower-dose cohort of its ongoing phase I/II clinical trial of AMT-130 for treating Huntington's disease.

Calliditas (CALT) obtains accelerated approval for Tarpeyo to reduce proteinuria in IgA nephropathy in the United States.

Foghorn (FHTX) soars following a collaboration with pharma giant Lilly for novel oncology targets.

Bristol-Myers (BMY) increases its quarterly dividend and announces a share repurchase program. Consequently, the stock gains.

Intercept (ICPT) withdraws its application seeking approval for OCA for the treatment of liver fibrosis due to nonalcoholic steatohepatitis in the EU. Resultantly, the stock declines.

Dare (DARE) gets FDA approval for Xaciato (clindamycin phosphate) vaginal gel as a treatment for bacterial vaginosis.

Radius Health (RDUS) provides detailed results on breast cancer drug and from the phase III wearABLe study.

AbbVie's (ABBV) Rinvoq achieves primary and key secondary endpoints in the first phase III induction study in patients with Crohn's Disease.

Viking Therapeutics, Inc. (VKTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising ea